Insilico Medicine– tag –
-
Insilico Medicine and Bora Pharmaceuticals Form Multi-Billion Dollar AI-Driven Drug Discovery and Manufacturing Alliance
News-Medical.Net USA Overview Insilico Medicine and Bora Pharmaceuticals have announced a strategic multi-target alliance with a potential value exceeding US$2.5 billion. This partnership integrates Insilico's Pharma.AI platform with Bor... -
Insilico Medicine to Showcase AI Drug Discovery Progress at Global Summits: Dr. Aliper to Keynote in Geneva, Dr. Zhavoronkov to Present Breakthroughs in Hong Kong
Insilico Medicine (via News-Medical.net) Unknown Overview Insilico Medicine announced that Co-Founder and President Dr. Alex Aliper will deliver a keynote on AI-powered drug discovery and generative AI in pharma R&D at the "AI for Go... -
First AI-Designed Drug Poised for FDA Approval by 2026-2027: Insilico Medicine’s IPF Candidate Leads
Oncodaily USA Overview The first AI-designed drug is increasingly likely to gain FDA approval between 2026 and 2027, with Insilico Medicine's rentosertib for idiopathic pulmonary fibrosis (IPF) identified as the leading candidate. Eli Li... -
Challenges in AI Drug Discovery Clinical Success Rates: Insilico’s Lenticelib First to Phase II, AlphaFold Accelerates Structural Biology
MDPI Switzerland Overview While AI drug discovery accelerates early-stage discovery, consistent improvement in late-stage clinical trial success rates remains a challenge. However, Insilico Medicine's lenticelib (NCT05938920) has become ... -
Insilico Medicine’s AI Drug Discovery Accelerates: Lenticelib, First AI-Designed Target and Structure, Achieves IND in 18 Months and Enters Mid-Stage Clinical Trials
Forever.ai (Appears to be a scientific review/journal) Unknown Overview AI drug discovery is dramatically reducing early-stage discovery timelines from years to mere weeks or months, encompassing target selection, hit identification, lea... -
AI-Designed Drugs from DeepMind’s AlphaFold, Insilico, and Generate Biomedicines Advance to Mid-Late Stage Clinical Trials, Intensifying Drug Discovery Race
MedCity News USA Overview The AI drug discovery sector is intensifying as advanced AI-designed drugs are poised to deliver mid-to-late stage clinical trial results within the next two years, leveraging breakthroughs like DeepMind's Alpha... -
AI Drug Discovery Investment Surges to $10 Billion in 2026 with Eli Lilly Partnerships and Over 173 Clinical Programs, Highlighting Isomorphic Labs
MarketWise USA Overview Investment in AI drug discovery is booming in 2026, following Anthropic's CEO's prediction of a biotech renaissance, with AI and ML-related biopharma deals already nearing $10 billion. Key drivers include Eli Lill... -
Leading AI Drug Discovery Platforms Evolve from Candidate Generation to Protein Design in 2026, Driven by Eli Lilly-Insilico Medicine $2.75 Billion Partnership
The AI Journal USA Overview In 2026, AI drug discovery platforms, led by Converge Bio, Xaira Therapeutics, and Generate Biomedicines, have advanced beyond mere drug prediction to encompass candidate generation, antibody engineering, targ... -
Insilico Medicine Initiates Phase 1 Trial for AI-Designed Brain-Penetrant NLRP3 Inhibitor ISM8969 for Neuroinflammation
World Pharma Today Hong Kong Overview Insilico Medicine has completed dosing of the first patient in a Phase 1 trial for ISM8969, an AI-designed brain-penetrant NLRP3 inhibitor targeting neuroinflammatory and CNS diseases like Parkinson'... -
ThinkBio.Ai Leads AI Drug Discovery Tools Market, Innovating Target Identification and Clinical Trial Planning
BioStock Info スウェーデン Overview AI is generating significant value across drug discovery by enhancing target identification, drug repurposing, and clinical trial planning. Platforms like ThinkBio.Ai, Schrödinger, and Insilico Medicin...
